Novo Nordisk trains sights on Roche with "aggressive" hemophilia drug development

With a stated goal of outstripping Roche's Hemlibra, Novo Nordisk has assumed the full risk of a potential hemophilia drug resulting from a collaboration with Genmab.

Photo: Novo Nordisk / PR

Novo Nordisk has big dreams for its potential hemophilia treatment, Mim8, but its main goal is beating Roche.

CEO at Novo Nordisk Lars Fruergaard Jørgensen says as much in an interview with Danish business daily Børsen, declaring that Mim8 is designed to beat Roche's Hemlibra.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs